Search Results

2025 was a year of meaningful progress in neuroendocrine cancer. New treatments, new clinical trial data, and expanded research efforts continue to improve care for people living with diverse neuroendocrine cancers including neuroendocrine tumor (NET), neuroendocrine carcinoma (NEC), and pheochromocytoma and paraganglioma (PPGL). Below is an overview of some of the most important developments of the year. Year-in-Review: NET and NEC Updates Download the transcript of this video >>> Dr. Udhay Grewal summarizes major advances from conferences and clinical trials across the NET and NEC landscape. Key Advances Continued progress in alpha PRRT, including completion of the ACTION 1 Actinium 225 trial. FDA approval of belzutifan for pheochromocytoma and paraganglioma. Promising results from DLL3 targeted therapies for high grade NEC. Ongoing development of tri-specific antibodies and DLL3 radioligand therapies. New Developments in Neuroendocrine Tumors (NETs) Download the transcript of this video >>> 2025 brought several promising updates for patients with well-differentiated NETs. Dr. Aman Chauhan highlights the following: Key Advances Paltusotine : A once-daily pill being studied for carcinoid syndrome. Alpha PRRT : Early activity seen with Lead-212 and Actinium-225 therapies. Combination PRRT : Triapine plus Lutetium-177 shows encouraging safety and early effectiveness. New targeted therapy : Zanzalintinib is being evaluated as a next-generation VEGF inhibitor. New Developments in Neuroendocrine Carcinoma (NEC) Download the transcript of this video >>> High-grade NEC has historically had fewer treatment options, but 2025 delivered real momentum. Dr. Aman Chauhan discusses the following: Key Advances DLL3 T-cell engagers:  Including tarlatamab and the investigational drug obrixtamig. Oncolytic virus therapy:  Seneca Valley Virus combined with immunotherapy is being studied. DLL3 radiopharmaceuticals:  New therapies under development that may bring theranostics to NEC. COMPETE Trial Results Presented at ENETS 2025 Download the transcript of this video >>> At the ENETS Congress in March 2025, NANETS President Emeritus Dr. Halfdanarson explained key results from the COMPETE phase 3 trial comparing PRRT Lu 177 DOTATOC with everolimus. He also discusses what it means for patients. Key Takeaways PRRT was more effective than everolimus in delaying tumor growth. Side effects were expected and consistent with previously known PRRT safety. Quality-of-life data are pending, but past studies suggest favorable outcomes. Everolimus remains an important option. The goal is ensuring patients receive all effective treatments over time. 2025 Highlights and Future Directions from NANETS President Dr. Jennifer Chan Download the transcript of this video >>> At the September 2025 INCA Summit in Sofia, Bulgaria, NANETS President, Dr. Jennifer Chan reflected on the progress of the past year and shared what she is most excited about for the future: Key Highlights Cabozantinib approval  Dr. Chan discussed the impact of cabozantinib’s approval for both pancreatic and extra pancreatic NETs and described how this expands treatment access for patients worldwide. Belzutifan approval for PPGL   She highlighted the approval of belzutifan as a major step forward for people with pheochromocytoma and paraganglioma. Broader research momentum  Growth in the number of physicians, scientists, and centers engaged in NET and NEC research has transformed the field. Upcoming trial readouts  Dr. Chan emphasized the importance of recently completed studies, including COMPETE, and expressed enthusiasm for ongoing alpha PRRT studies and other next generation therapies. Cabozantinib Results Highlighted at ESMO 2025 Download the transcript of this video >>> In October 2025, new subgroup data on lung and thymic NET from the CABINET study were presented at ESMO. This followed the FDA approval of cabozantinib in March 2025. Dr. Aman Chauhan explains what this means for patients: Key Takeaways Strong benefit seen in lung NETs, including typical and atypical carcinoids. Activity observed in higher grade well-differentiated NETs. An important treatment option for people who are not eligible for PRRT or somatostatin analogs. NANETS 2025: Top 12 Highlights Our Neuroendocrine Cancer Foundation podcast with Dr. Will Pegna offers an easy-to-understand review of the most important updates from the 2025 NANETS symposium. Visit the podcast page for more information and resources >>> Bridging Inequities in Neuroendocrine Cancer Care Download the transcript of this video >>> A meaningful highlight of 2025 was the growing recognition of inequities in neuroendocrine cancer care and the expanding commitment across the field to address them. Dr. Grewal, who was honored with the inaugural NANETS Diversity, Equity, and Inclusion Award, shared why this work is essential and how patients and advocates can help drive meaningful change. Key Insights Many patients seen in everyday practice do not resemble those typically enrolled in clinical trials. Racial and ethnic minority groups, as well as rural patients, often face major barriers to receiving standard of care treatment and participating in research. Recent studies highlight disparities in clinical trial enrollment and end-of-life care, including lower access to palliative care among Black patients. Researchers are using NETPRO and other datasets to better understand gaps and inform future solutions. Why This Matters Dr. Udhay Grewal emphasized that progress is meaningful only when it reaches everyone who needs it. As new therapies emerge, ensuring equitable access is essential. How Patients and Caregivers Can Help Get involved in advocacy and awareness efforts. Share your experiences to help shape research and improve care. Partner with organizations like NCF, NANETS, and ASCO to support equity-focused initiatives. Looking Ahead to 2026 We look forward to the launch of new clinical trials and the results of several important ongoing studies, including those evaluating combination PRRT strategies, multiple alpha PRRT agents, DLL3-targeted therapies, and new oral treatment options. Progress is accelerating, and as research expands, so do the treatment options and sources of hope available to patients. As our speakers emphasized, meaningful advances are happening. There is real reason to be hopeful. And together, we can continue to move the field forward.  THANKS TO OUR SPONSORS

"I was diagnosed with neuroendocrine tumors in 2022. I had never heard of this disease before, and I lived in a state without a single NET specialist. I was scared and unsure of what to do next. I am so thankful that I quickly reached out to the Neuroendocrine Cancer Foundation (NCF). One of the first NCF emails I received said, ' You are not alone. We are here to help.'  In the midst of uncertainty and fear, they offered hope . From the very beginning, NCF connected me with someone who understood this disease in a way that my friends and family simply could not. That early support helped steady me when everything felt confusing. As time went on, those first conversations grew into friendships that have stayed with me. I still look back and cannot believe how much this community has meant to me. This disease, which felt so isolating at first, has offered me one of the richest experiences of community  I’ve ever encountered. One of the most important things NCF has given me is an understanding of my disease and the confidence to take part in my own care. Those early months were filled with new tests, unfamiliar terms, and decisions that felt incredibly heavy. The education I received helped me walk into appointments prepared instead of afraid. It changed how I spoke with my doctors and how I saw myself in this process. Those early days were so full of confusion, but now I am equipped with knowledge  thanks to the countless educational resources NCF provides. Because of NCF, I no longer feel powerless in the face of this disease. I can advocate for myself and for others. I have shared my story, participated in research, been proactive in my care, and supported newly diagnosed patients with a deep sense of purpose and empowerment. None of this happens by accident. It exists because  people like me—and like you— choose to support this organization because we believe that patients deserve guidance, clarity, encouragement, and connection. Every resource I used and every moment of understanding I gained came from someone who cared enough to give. Your support is transformative in the lives of neuroendocrine cancer patients who benefit from the wide range of programs and resources NCF provides to support people living well with neuroendocrine cancer." "Your generosity makes all of this possible. In 2026, an estimated 12,000 to 23,000 people in the United States will be diagnosed with neuroendocrine cancer. You help ensure that the next person who hears a diagnosis of "neuroendocrine tumor" does not have to navigate this disease alone.  Thank you for making a difference in my life and in the lives of so many others." With Deep Gratitude,  Dusty Hurley  Donations (Up to $50,000) will be matched dollar for dollar until Dec 31, 2025. Dusty Hurley is wife to a charming Irishman; mom to two loving, fun, and bright elementary-aged daughters; and the favorite human of two fluffy, playful dogs. Her professional background includes ministry, nonprofit and government leadership, and grant writing. She enjoys spending time with friends and family…bonus points if it can be around a campfire or traveling to somewhere new. Diagnosed with a pancreatic neuroendocrine tumor (pNET) in 2022, Dusty brings faith, optimism, and determination to her roles as both patient and advocate. She’s passionate about helping others navigate NET with clarity, courage, and hope. Watch Dusty on a recent patient panel: "Living With NET: A Patient Perspective."  THANKS TO OUR SPONSORS

The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors.  “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada.  Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median Progression Free Survival (PFS) to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).  NETTER-2 is the first and only positive Phase III trial for a radioligand therapy (RLT) or PRRT in the first-line setting, demonstrating the potential of RLTs in earlier treatment lines. Novartis is investigating a broad portfolio of RLTs or PRRT in advanced cancers, in addition to GEP-NETs, including lung, prostate, breast, colon, glioblastoma and pancreatic cancers to continue reimagining medicine for patients. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors

The Neuroendocrine Cancer Foundation serves the neuroendocrine cancer (or NET) community by connecting patients, caregivers, and medical professionals. Find educational resources and connect with other NET patients and caregivers. REGISTER Podcast Blog Resources by Topic LATEST FROM NCF New Podcast Episode - "Spotlight on Genetic Counselors" with Samantha Greenberg Register: "The Latest in Neuroendocrine Cancer Clinical Trials" with Dr. Soares on Feb 20, 2026 Register: "Zeal For Life" Movie Screening - Los Angeles, CA "2025 Highlights in Neuroendocrine Cancer" New Blogpost - "The Email That Changed Everything" - Dusty Hurley New Educational Event - "The Latest on Immunotherapy for Neuroendocrine Cancer" with Dr. Aman Chauhan New Podcast Episode - "Spotlight on Pharmacists" with Amanda Cass, PharmD, BCPS, BCOP Watch "2025 Updates in NET" with Dr. Aman Chauhan Watch "The Latest in High-Grade Neuroendocrine Carcinoma (NEC)" with Dr. Aman Chauhan Watch "The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal" Watch "Bridging Inequities in Neuroendocrine Cancer Care: A Conversation" with Dr. Udhayvir Grewal Clinical Trial Update - Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms Clinical Trial Update - ZL-1310 in Participants With Selected Solid Tumors SIGN UP FOR EMAIL Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE NCF EVENTS The Latest in Neuroendocrine Cancer Clinical Trials Feb 20, 2026 Virtual Register "Zeal for Life" - A Special Documentary Screening March 7, 2026 In-Person Register Visit our events page for more information >>> MAKE A DIFFERENCE Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide WATCH 500+ Videos on Various Topics 2025 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn How You Can Share Your Story RECENT EDUCATIONAL EVENTS FOR PATIENTS Play Video Play Video 01:31:30 The Latest on Immunotherapy for Neuroendocrine Cancer • 2025 NCF Event • Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is the national principal investigator on several investigator-initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Visit https://www.ncf.net/events/dec2025 for more information. Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. Play Video Play Video 01:30:51 "Understanding Treatments for NETs and Rationale for Sequencing of Therapy" • Dr. Wolin • Apr 1, 25 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. Learn more at https://www.ncf.net/events/apr2025 Play Video Play Video 01:49:57 "PRRT Nurse's Perspective: What to Expect with PRRT" • Linda Gardner, MSN, RN, VA-BC • Mar 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Learn more at https://www.ncf.net/events/mar2025 Play Video Play Video 01:28:12 "Deciphering Genetics & Genomics in Neuroendocrine Cancers" • Dr. Perez • Feb 7, 25 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Learn more at LACNETS.org. LATEST PODCAST EPISODES LISTEN LISTEN LISTEN LISTEN RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine cancer experts answer the top 10 FAQs on various topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers ABOUT THE NEUROENDOCRINE CANCER FOUNDATION Why Our Work Matters The Neuroendocrine Cancer Foundation (NCF) exists to ensure no one faces neuroendocrine cancer alone. We support patients, caregivers, and clinicians through education, connection, and compassionate resources. Educate Educational Events Luncheon With The Experts w/Live Q&A In-Person Patient & Caregiver Events Online Video Library (YouTube & Web) Resource Library on 25 Topics Podcast Spanish Resources Support Support Line Resources for Newly Diagnosed Support Groups Health & Wellness Retreat Wellness Coaching Connect NETCONNECT Peer-to-Peer Program NET VITALS NET INTRO Inform Clinical Trials Guide Amplify Patient Voice Neuroendocrine cancer (also known as NET, neuroendocrine tumor, neuroendocrine neoplasm, carcinoid, or neuroendocrine carcinoma) is a rare/uncommon and complex disease. Only 7 in 100,000 people in the U.S. are diagnosed each year Symptoms vary widely and are often misunderstood Diagnosis can take several years Many patients do not meet someone else living with NET until they find NCF Patients often struggle to find specialists, up-to-date treatment guidance, and emotional support. NCF fills those gaps by offering what patients need most: credible education, expert access, and a community that understands. NCF provides these life-changing resources — ensuring patients and families receive guidance when it matters most. I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient

Upcoming Events & Meetings The Latest in Neuroendocrine Cancer Clinical Trials Friday, Feb 20, 2026 Learn about the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, medical oncologist and physician-scientist at the Huntsman Cancer Institute in Salt Lake City. She will highlight key trials and explain why they matter for patients and caregivers. Register Special Screening of 'Zeal for Life' Saturday, March 7, 2026 Join the Neuroendocrine Cancer Foundation on Saturday afternoon, March 7th, for a special screening of Zeal for Life. Register Novel Targeted Therapies in Neuroendocrine Cancers Mar 9, 2026 Learn about targeted therapies in neuroendocrine cancer—a rapidly growing area of treatment—with Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center. This webinar will explain how targeted therapies work, and explore novel treatments in this category including current clinical trials. Register Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand Apr 23, 2026 Learn the essentials of navigating a new neuroendocrine cancer diagnosis with Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City. When first diagnosed, many patients feel overwhelmed and wonder, “What is neuroendocrine cancer, and how is it different from other cancers?” This webinar will explain what makes NETs unique, key concepts like grade and stage, and the most important first steps and questions to help you understand your diagnosis with more clarity and confidence. Register Neuroendocrine Cancer Patient Conference Saturday, May 16, 2026 Atlanta, GA The Neuroendocrine Cancer Foundation will host an in-person educational event for patients and caregivers in Atlanta, GA, on May 16, 2026. Register Neuroendocrine Cancer Patient Conference (Virtual) Saturday, June 20, 2026 The Neuroendocrine Cancer Foundation will host a virtual educational event for patients and caregivers on June 20, 2026. Opening Soon Virtual NET Patient & Caregiver Support Group (Weekly) Feb 4, 11, 18 & 25, 2026 NOON - 1:30 PM Pacific Join NCF via ZOOM Weekly on Wednesdays from 12 - 1:30 PM Pacific Time. We provide a collective, empathetic space for information & experience sharing, support & community. For NET Patients & Caregivers Register Virtual NET Caregiver Support Group (Monthly on a Saturday) Next meeting 2/28/26, 8:00 - 10:00 AM Pacific We provide a space where NET caregivers can come together virtually for support and community. We encourage you to express your experiences, thoughts, and concerns amongst fellow caregivers. For NET caregivers only Register Click here for recent events

< Back to the upcoming events page REGISTER Some Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation will focus on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources . ASK YOUR QUESTIONS Submit your general questions for the Live Q&A. Speaker cannot answer case-specific questions. ABOUT DR. HELOISA P. SOARES Medical Oncologist Huntsman Cancer Institute (HCI) University of Utah Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79 RESOURCES The Latest on Immunotherapy for Neuroendocrine Cancer with Dr. Aman Chauhan (Dec 2025) Additional Clinical Trials Resources: https://www.ncf.net/clinical-trials/additional-resources "Navigating Clinical Trials: Expectations vs. Realities" with Taymeyah Al-Toubah • Aug 2023 Clinical Trials: Why, What & How • Josh Mailman • 2023 Patient Education Conference THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.